Home | SOAP Tools | UDDI Browser | ResourcesSource Code | RFCs | News Reader  | SOAP Interop | Bookmarks 

  

General
Reuters
CNN
Wired News
News.com
CBS News
NY Time
BBC
BBC World
Google News
Yahoo News
ABC News
Political Wire
WashingtonPost
WorldPress
US News
CS Monitor
Business
NY Time
CNN
Reuter
ABC News
CBS News
BBC Business
Forbes
Technology
CNET
CNN
Reuter
NY Time
WashingtonPost
Wired News
BBC
InfoWorld
InfoWorld WS
WebReference
LinuxToday
XML.com
XML Cover Pages
OASIS
W3C
Internet.com
JavaScript Tip
Linux Today
WDVL
CodeProject
SOAPAgent.com
Articles
Web Services
SOAP Resources
New Additions
Software Download
Most Popular
New Releases
Hot Title
Software Developer
Yahoo News
Top Stories
World
Business
Technology
Politics
Science
Sports
New York Times
Home Page
World
Business
Technology
Politics
Science
Sports
Reuters
Top News
World
Business
Technology
World News
CNN
CBS
WashingtonPost
RSS News Feeds
ChannelYahoo News - Latest News & Headlines    
RSS File: https://news.yahoo.com/rss/business
Description: The latest news and headlines from Yahoo! News. Get breaking news stories and in-depth coverage with videos and photos.
  • Voting 2020 live updates: Supreme Court blocks curbside voting in Alabama; Delaware voters won't be forced to wear masks      Sat, 24 Oct 2020 12:35:27 -0400

    Voting 2020 live updates: Supreme Court blocks curbside voting in Alabama; Delaware voters won't be forced to wear masksPresident Trump expected to vote in West Palm Beach. Delaware voters don't have to wear masks. Advice on how to vote. Latest news from across the U.S.


    Voting 2020 live updates: Supreme Court blocks curbside voting in Alabama; Delaware voters won't be forced to wear masksPresident Trump expected to vote in West Palm Beach. Delaware voters don't have to wear masks. Advice on how to vote. Latest news from across the U.S.


     

  • Sorry, but you need to upgrade your phone every year now      Sat, 24 Oct 2020 12:33:51 -0400

    Sorry, but you need to upgrade your phone every year nowThe trade-in deals and buyback offers are just too good for the recent ones, which gives you about half-off new price. $500 or so for a year's use?


    Sorry, but you need to upgrade your phone every year nowThe trade-in deals and buyback offers are just too good for the recent ones, which gives you about half-off new price. $500 or so for a year's use?


     

  • The Electoral College can pick a president who got less votes. Here's why and how.      Sat, 24 Oct 2020 12:28:45 -0400

    The Electoral College can pick a president who got less votes. Here's why and how.The 2020 presidential election again highlights one of the most confusing and controversial parts of the U.S. elections: The Electoral College.


    The Electoral College can pick a president who got less votes. Here's why and how.The 2020 presidential election again highlights one of the most confusing and controversial parts of the U.S. elections: The Electoral College.


     

  • SpaceX launches 60 more satellites during 15th Starlink mission      Sat, 24 Oct 2020 12:27:43 -0400

    SpaceX launches 60 more satellites during 15th Starlink missionSpaceX has launched another batch of 60 Starlink satellites, the primary ingredient for its forthcoming global broadband internet service. The launch took place at 11:31 AM EDT, with a liftoff from Cape Canaveral Air Force Station in Florida. This is the fifteenth Starlink launch thus far, and SpaceX has now launched nearly 900 of the small, low Earth orbit satellites to date.


    SpaceX launches 60 more satellites during 15th Starlink missionSpaceX has launched another batch of 60 Starlink satellites, the primary ingredient for its forthcoming global broadband internet service. The launch took place at 11:31 AM EDT, with a liftoff from Cape Canaveral Air Force Station in Florida. This is the fifteenth Starlink launch thus far, and SpaceX has now launched nearly 900 of the small, low Earth orbit satellites to date.


     

  • Afghan bombing: Kabul education centre attack kills at least 18      Sat, 24 Oct 2020 12:19:38 -0400

    Afghan bombing: Kabul education centre attack kills at least 18A suicide bomber detonates explosives in the Afghan capital, wounding 50 other people.


    Afghan bombing: Kabul education centre attack kills at least 18A suicide bomber detonates explosives in the Afghan capital, wounding 50 other people.


     

  • Festi hf.: Buy-back programme week 43      Sat, 24 Oct 2020 12:18:00 -0400

    Festi hf.: Buy-back programme week 43In week 43 Festi purchased in total 750.000 shares:   Purchased PurchaseOwn shares total WeekDateTimesharesShare pricepriceat end of day         4319.10.202009:44:51       150.000    149,7522.462.500 kr            7.195.407     4320.10.202009:45:58       150.000    153,2522.987.500 kr            7.345.407     4321.10.202009:54:24       150.000    154,0023.100.000 kr            7.495.407     4322.10.202009:43:17       150.000    155,0023.250.000 kr            7.645.407     4323.10.202009:45:31       150.000    155,0023.250.000 kr            7.795.407                       750.000     115.050.000 kr  This announcement of purchase of own shares is in accordance with the buy-back programme announced 4 October 2020 to Nasdaq OMX Iceland. The programme envisages the buy-back of a total of 4.000.000 own shares or 1.2% of the issued shares, with the cap of 600 million ISK purchase price.Before the purchase Festi held 5.645.407 shares or 1.70% of issued shares. Festi today holds 7.795.407 shares or 2.34% of issued shares.The execution the buy-back programme is in accordance with Chapter VIII of the Company Act No 2/1995 and annex II to the Regulation on insider information and market abuse No 630/2005.For further information contact Eggert Þór Kristófersson, CEO of Festi hf., (eggert@festi.is) and Magnús Kr. Ingason, CFO of Festi hf. (mki@festi.is).


    Festi hf.: Buy-back programme week 43In week 43 Festi purchased in total 750.000 shares:   Purchased PurchaseOwn shares total WeekDateTimesharesShare pricepriceat end of day         4319.10.202009:44:51       150.000    149,7522.462.500 kr            7.195.407     4320.10.202009:45:58       150.000    153,2522.987.500 kr            7.345.407     4321.10.202009:54:24       150.000    154,0023.100.000 kr            7.495.407     4322.10.202009:43:17       150.000    155,0023.250.000 kr            7.645.407     4323.10.202009:45:31       150.000    155,0023.250.000 kr            7.795.407                       750.000     115.050.000 kr  This announcement of purchase of own shares is in accordance with the buy-back programme announced 4 October 2020 to Nasdaq OMX Iceland. The programme envisages the buy-back of a total of 4.000.000 own shares or 1.2% of the issued shares, with the cap of 600 million ISK purchase price.Before the purchase Festi held 5.645.407 shares or 1.70% of issued shares. Festi today holds 7.795.407 shares or 2.34% of issued shares.The execution the buy-back programme is in accordance with Chapter VIII of the Company Act No 2/1995 and annex II to the Regulation on insider information and market abuse No 630/2005.For further information contact Eggert Þór Kristófersson, CEO of Festi hf., (eggert@festi.is) and Magnús Kr. Ingason, CFO of Festi hf. (mki@festi.is).


     

  • Statement from the Chief Public Health Officer of Canada on October 24, 2020      Sat, 24 Oct 2020 12:18:00 -0400

    Statement from the Chief Public Health Officer of Canada on October 24, 2020OTTAWA, ON, Oct. 24, 2020 /CNW/ - In lieu of an in-person update to the media, Dr.


    Statement from the Chief Public Health Officer of Canada on October 24, 2020OTTAWA, ON, Oct. 24, 2020 /CNW/ - In lieu of an in-person update to the media, Dr.


     

  • LOOP INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in that a Securities Class Action Lawsuit has been Filed Against Loop Industries Inc.      Sat, 24 Oct 2020 12:09:00 -0400

    LOOP INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in that a Securities Class Action Lawsuit has been Filed Against Loop Industries Inc.NEW YORK, NY / ACCESSWIRE / October 24, 2020 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the securities of Loop Industries ("Loop" or the "Company") (NASDAQ:LOOP) between September 24, 2018 and October 12, 2020 (the "Class Period").


    LOOP INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in that a Securities Class Action Lawsuit has been Filed Against Loop Industries Inc.NEW YORK, NY / ACCESSWIRE / October 24, 2020 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the securities of Loop Industries ("Loop" or the "Company") (NASDAQ:LOOP) between September 24, 2018 and October 12, 2020 (the "Class Period").


     

  • Anviz Launches New Generation Face Recognition Solutions in Response to Post-Pandemic World      Sat, 24 Oct 2020 12:00:00 -0400

    Anviz Launches New Generation Face Recognition Solutions in Response to Post-Pandemic WorldIn the past couple of months, the COVID-19 pandemic has caused multiple disruptions and safety concerns for organizations across every industry. As businesses struggle to create a safe, comfortable return for employees, customers, and vendors, touchless and thermal management has become an integral part of requirements in providing immediate, visual scanning solutions.


    Anviz Launches New Generation Face Recognition Solutions in Response to Post-Pandemic WorldIn the past couple of months, the COVID-19 pandemic has caused multiple disruptions and safety concerns for organizations across every industry. As businesses struggle to create a safe, comfortable return for employees, customers, and vendors, touchless and thermal management has become an integral part of requirements in providing immediate, visual scanning solutions.


     

  • How much switching to an electric vehicle could really save you      Sat, 24 Oct 2020 12:00:00 -0400

    How much switching to an electric vehicle could really save youBuying an EV can be daunting, but a new report shows how worthwhile the investment can be.


    How much switching to an electric vehicle could really save youBuying an EV can be daunting, but a new report shows how worthwhile the investment can be.


     

  • COVID-19 Pandemic - The government presents its daily update      Sat, 24 Oct 2020 11:53:00 -0400

    COVID-19 Pandemic - The government presents its daily updateQUÉBEC CITY, Oct. 24, 2020 /CNW Telbec/ - The most recent data on the evolution of COVID-19 in Québec show 1,009 new cases, bringing the total number of people infected to 99,235.


    COVID-19 Pandemic - The government presents its daily updateQUÉBEC CITY, Oct. 24, 2020 /CNW Telbec/ - The most recent data on the evolution of COVID-19 in Québec show 1,009 new cases, bringing the total number of people infected to 99,235.


     

  • Hundreds protest in London against Nigeria violence      Sat, 24 Oct 2020 11:44:59 -0400

    Hundreds protest in London against Nigeria violenceAround 500 demonstrators took to the streets of London on Saturday in support of youth protests in Nigeria that have spiralled into widespread unrest.


    Hundreds protest in London against Nigeria violenceAround 500 demonstrators took to the streets of London on Saturday in support of youth protests in Nigeria that have spiralled into widespread unrest.


     

  • Bitcoin’s Rivalry With Gold Plus Millennial Interest Gives It ‘Considerable’ Upside Potential: JPMorgan      Sat, 24 Oct 2020 11:43:37 -0400

    Bitcoin’s Rivalry With Gold Plus Millennial Interest Gives It ‘Considerable’ Upside Potential: JPMorganA Friday note outlines institutional, corporate, and Millennial interest in the leading cryptocurrency.


    Bitcoin’s Rivalry With Gold Plus Millennial Interest Gives It ‘Considerable’ Upside Potential: JPMorganA Friday note outlines institutional, corporate, and Millennial interest in the leading cryptocurrency.


     

  • Trump casts a 'very secure vote' for himself in Florida: 2020 election updates      Sat, 24 Oct 2020 11:33:24 -0400

    Trump casts a 'very secure vote' for himself in Florida: 2020 election updates"I voted for a guy named Trump," the president said.


    Trump casts a 'very secure vote' for himself in Florida: 2020 election updates"I voted for a guy named Trump," the president said.


     

  • SPoT Coffee Comments on Reinstatement Review      Sat, 24 Oct 2020 11:30:00 -0400

    SPoT Coffee Comments on Reinstatement ReviewTORONTO, Oct. 24, 2020 /CNW/ - SPOT COFFEE (CANADA) LTD.


    SPoT Coffee Comments on Reinstatement ReviewTORONTO, Oct. 24, 2020 /CNW/ - SPOT COFFEE (CANADA) LTD.


     

  • Exclusive: Leading investors in Ant Shanghai IPO submit bids in 68-69 yuan/share range, say sources      Sat, 24 Oct 2020 11:14:17 -0400

    Exclusive: Leading investors in Ant Shanghai IPO submit bids in 68-69 yuan/share range, say sourcesSome large Chinese fund managers have submitted bids in the range of 68-69 yuan per share for the Shanghai leg of the financial technology giant Ant Group's likely $35 billion dual-listing, people with direct knowledge of the matter said. Many of them have bid for the Ant shares for the domestic listing at the Nasdaq-style STAR Market in Shanghai at close to 69 yuan ($10.32) apiece, one source said. The expected $35 billion listing in Hong Kong and Shanghai of Ant, backed by e-commerce behemoth Alibaba, would be the world's largest IPO, beating Saudi Aramco's record $29.4 billion float last December.


    Exclusive: Leading investors in Ant Shanghai IPO submit bids in 68-69 yuan/share range, say sourcesSome large Chinese fund managers have submitted bids in the range of 68-69 yuan per share for the Shanghai leg of the financial technology giant Ant Group's likely $35 billion dual-listing, people with direct knowledge of the matter said. Many of them have bid for the Ant shares for the domestic listing at the Nasdaq-style STAR Market in Shanghai at close to 69 yuan ($10.32) apiece, one source said. The expected $35 billion listing in Hong Kong and Shanghai of Ant, backed by e-commerce behemoth Alibaba, would be the world's largest IPO, beating Saudi Aramco's record $29.4 billion float last December.


     

  • Fact check: COVID-19 vaccine won't be ready in weeks, nor mandatory      Sat, 24 Oct 2020 11:14:02 -0400

    Fact check: COVID-19 vaccine won't be ready in weeks, nor mandatoryVaccine conspiracy theories that originated in anti-vaxxer communities have thrived anew in the COVID-19 era


    Fact check: COVID-19 vaccine won't be ready in weeks, nor mandatoryVaccine conspiracy theories that originated in anti-vaxxer communities have thrived anew in the COVID-19 era


     

  • Rep. Stefanik: ‘Joe Biden Is Lying to the American People’ about Hunter’s Business Dealings      Sat, 24 Oct 2020 11:12:22 -0400

    Rep. Stefanik: ‘Joe Biden Is Lying to the American People’ about Hunter’s Business DealingsDemocratic presidential nominee Joe Biden is “lying to the American people” about his son Hunter Biden’s foreign business dealings, claimed Representative Elise Stefanik (R., N.Y.) on Saturday.The House Intelligence Committee member's comments came during an appearance on Fox & Friends Weekend, in which she accused the former vice president of lying when he issued his denial of wrongdoing during Thursday night’s presidential debate. Stefanik detailed her experience asking each witness in President Trump’s impeachment hearings whether there was a conflict of interest, or an appearance of one, created by Hunter Biden’s role on the board of Ukrainian natural-gas firm Burisma Holdings during Joe Biden’s time as vice president. All of the witnesses said yes, she recalled.She said the Obama administration “proactively brought this up as a conflict of interest” while preparing former U.S. ambassador to Ukraine Marie Yovanovitch for her Senate nomination. “This is Joe Biden running from his record and trying to wipe away this very clear conflict of interest,” Stefanik said."This is not just a Hunter Biden scandal. This is a Joe Biden scandal, and it's not just Burisma. It's also now the Chinese Communist government and the Chinese Communist Party," she added, referring to allegations of a business arrangement between a Chinese company and the Biden family.During Thursday’s debate, the former vice president claimed there was “nothing unethical” about Hunter Biden’s involvement in Burisma.He said though questions had arisen over whether he had done something wrong in respect to Hunter Biden’s role on the board of Burisma that, “every single solitary person, when [Trump] was going through his impeachment, testifying under oath, who worked for him said I did my job impeccably, I carried out U.S. policy, not one single, solitary thing was out of line.”


    Rep. Stefanik: ‘Joe Biden Is Lying to the American People’ about Hunter’s Business DealingsDemocratic presidential nominee Joe Biden is “lying to the American people” about his son Hunter Biden’s foreign business dealings, claimed Representative Elise Stefanik (R., N.Y.) on Saturday.The House Intelligence Committee member's comments came during an appearance on Fox & Friends Weekend, in which she accused the former vice president of lying when he issued his denial of wrongdoing during Thursday night’s presidential debate. Stefanik detailed her experience asking each witness in President Trump’s impeachment hearings whether there was a conflict of interest, or an appearance of one, created by Hunter Biden’s role on the board of Ukrainian natural-gas firm Burisma Holdings during Joe Biden’s time as vice president. All of the witnesses said yes, she recalled.She said the Obama administration “proactively brought this up as a conflict of interest” while preparing former U.S. ambassador to Ukraine Marie Yovanovitch for her Senate nomination. “This is Joe Biden running from his record and trying to wipe away this very clear conflict of interest,” Stefanik said."This is not just a Hunter Biden scandal. This is a Joe Biden scandal, and it's not just Burisma. It's also now the Chinese Communist government and the Chinese Communist Party," she added, referring to allegations of a business arrangement between a Chinese company and the Biden family.During Thursday’s debate, the former vice president claimed there was “nothing unethical” about Hunter Biden’s involvement in Burisma.He said though questions had arisen over whether he had done something wrong in respect to Hunter Biden’s role on the board of Burisma that, “every single solitary person, when [Trump] was going through his impeachment, testifying under oath, who worked for him said I did my job impeccably, I carried out U.S. policy, not one single, solitary thing was out of line.”


     

  • Exclusive: Leading investors in Ant Shanghai IPO submit bids in 68-69 yuan/share range, say sources      Sat, 24 Oct 2020 11:02:20 -0400

    Exclusive: Leading investors in Ant Shanghai IPO submit bids in 68-69 yuan/share range, say sourcesSome large Chinese fund managers have submitted bids in the range of 68-69 yuan per share for the Shanghai leg of the financial technology giant Ant Group's likely $35 billion dual-listing, people with direct knowledge of the matter said. Many of them have bid for the Ant shares for the domestic listing at the Nasdaq-style STAR Market in Shanghai at close to 69 yuan ($10.32) apiece, one source said. The expected $35 billion listing in Hong Kong and Shanghai of Ant, backed by e-commerce behemoth Alibaba , would be the world's largest IPO, beating Saudi Aramco's record $29.4 billion float last December.


    Exclusive: Leading investors in Ant Shanghai IPO submit bids in 68-69 yuan/share range, say sourcesSome large Chinese fund managers have submitted bids in the range of 68-69 yuan per share for the Shanghai leg of the financial technology giant Ant Group's likely $35 billion dual-listing, people with direct knowledge of the matter said. Many of them have bid for the Ant shares for the domestic listing at the Nasdaq-style STAR Market in Shanghai at close to 69 yuan ($10.32) apiece, one source said. The expected $35 billion listing in Hong Kong and Shanghai of Ant, backed by e-commerce behemoth Alibaba , would be the world's largest IPO, beating Saudi Aramco's record $29.4 billion float last December.


     

  • Exclusive: Leading investors in Ant Shanghai IPO submit bids in 68-69 yuan/share range, say sources      Sat, 24 Oct 2020 11:02:20 -0400

    Exclusive: Leading investors in Ant Shanghai IPO submit bids in 68-69 yuan/share range, say sourcesSome large Chinese fund managers have submitted bids in the range of 68-69 yuan per share for the Shanghai leg of the financial technology giant Ant Group's likely $35 billion dual-listing, people with direct knowledge of the matter said. Many of them have bid for the Ant shares for the domestic listing at the Nasdaq-style STAR Market in Shanghai at close to 69 yuan ($10.32) apiece, one source said. The expected $35 billion listing in Hong Kong and Shanghai of Ant, backed by e-commerce behemoth Alibaba , would be the world's largest IPO, beating Saudi Aramco's record $29.4 billion float last December.


    Exclusive: Leading investors in Ant Shanghai IPO submit bids in 68-69 yuan/share range, say sourcesSome large Chinese fund managers have submitted bids in the range of 68-69 yuan per share for the Shanghai leg of the financial technology giant Ant Group's likely $35 billion dual-listing, people with direct knowledge of the matter said. Many of them have bid for the Ant shares for the domestic listing at the Nasdaq-style STAR Market in Shanghai at close to 69 yuan ($10.32) apiece, one source said. The expected $35 billion listing in Hong Kong and Shanghai of Ant, backed by e-commerce behemoth Alibaba , would be the world's largest IPO, beating Saudi Aramco's record $29.4 billion float last December.


     

  • Hitting the Books: Widespread DNA testing could intensify American racism      Sat, 24 Oct 2020 11:00:11 -0400

    Hitting the Books: Widespread DNA testing could intensify American racismEvery time we log on, our personal data including where we go, what we search for, who we interact with and what we buy is scraped, siphoned, collected, analyzed, categorized and monetized in the everlasting effort to design and distribute more effective, more personalized advertising. In her latest book, Cyber Privacy: Who Has Your Data and Why You Should Care cybersecurity expert April Falcon Doss examines what sorts of data are being collected, how they’re being used (to both our benefit and detriment) and what can be done to keep your digital life history from being leaked across the internet. In the excerpt below, Doss takes a terrifying look at how our infatuation with Ancestry.com and other genealogical testing services has metastasized into a means for the Border Patrol and ICE to further harass and discriminate against black and brown people in America.


    Hitting the Books: Widespread DNA testing could intensify American racismEvery time we log on, our personal data including where we go, what we search for, who we interact with and what we buy is scraped, siphoned, collected, analyzed, categorized and monetized in the everlasting effort to design and distribute more effective, more personalized advertising. In her latest book, Cyber Privacy: Who Has Your Data and Why You Should Care cybersecurity expert April Falcon Doss examines what sorts of data are being collected, how they’re being used (to both our benefit and detriment) and what can be done to keep your digital life history from being leaked across the internet. In the excerpt below, Doss takes a terrifying look at how our infatuation with Ancestry.com and other genealogical testing services has metastasized into a means for the Border Patrol and ICE to further harass and discriminate against black and brown people in America.


     

  • Volcon Grunt is an electric motorcycle you can ride underwater      Sat, 24 Oct 2020 11:00:00 -0400

    Volcon Grunt is an electric motorcycle you can ride underwaterThe number of companies preparing to fight for a slice of the burgeoning electric off-roader segment grows on a regular basis, but Texas-based Volcon thinks it has what it takes to stand out. It unveiled a battery-powered motorcycle named Grunt with about 100 miles of range and the ability to operate under water. Although it wasn't designed as a submarine, the Grunt is powered by a drivertain that's IP67-rated, which means it can spend up to 30 minutes under roughly 40 inches of water without sustaining damage.


    Volcon Grunt is an electric motorcycle you can ride underwaterThe number of companies preparing to fight for a slice of the burgeoning electric off-roader segment grows on a regular basis, but Texas-based Volcon thinks it has what it takes to stand out. It unveiled a battery-powered motorcycle named Grunt with about 100 miles of range and the ability to operate under water. Although it wasn't designed as a submarine, the Grunt is powered by a drivertain that's IP67-rated, which means it can spend up to 30 minutes under roughly 40 inches of water without sustaining damage.


     

  • We're Hopeful That enCore Energy (CVE:EU) Will Use Its Cash Wisely      Sat, 24 Oct 2020 10:57:44 -0400

    We're Hopeful That enCore Energy (CVE:EU) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...


    We're Hopeful That enCore Energy (CVE:EU) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...


     

  • Analysts Have Made A Financial Statement On Northern Trust Corporation's (NASDAQ:NTRS) Third-Quarter Report      Sat, 24 Oct 2020 10:57:15 -0400

    Analysts Have Made A Financial Statement On Northern Trust Corporation's (NASDAQ:NTRS) Third-Quarter ReportShareholders might have noticed that Northern Trust Corporation (NASDAQ:NTRS) filed its quarterly result this time...


    Analysts Have Made A Financial Statement On Northern Trust Corporation's (NASDAQ:NTRS) Third-Quarter ReportShareholders might have noticed that Northern Trust Corporation (NASDAQ:NTRS) filed its quarterly result this time...


     

  • Here's What We Like About Sierra Bancorp's (NASDAQ:BSRR) Upcoming Dividend      Sat, 24 Oct 2020 10:53:57 -0400

    Here's What We Like About Sierra Bancorp's (NASDAQ:BSRR) Upcoming DividendReaders hoping to buy Sierra Bancorp (NASDAQ:BSRR) for its dividend will need to make their move shortly, as the stock...


    Here's What We Like About Sierra Bancorp's (NASDAQ:BSRR) Upcoming DividendReaders hoping to buy Sierra Bancorp (NASDAQ:BSRR) for its dividend will need to make their move shortly, as the stock...


     

  • Is Fortinet, Inc.'s (NASDAQ:FTNT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?      Sat, 24 Oct 2020 10:52:16 -0400

    Is Fortinet, Inc.'s (NASDAQ:FTNT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?Fortinet's (NASDAQ:FTNT) stock is up by a considerable 9.5% over the past month. Given the company's impressive...


    Is Fortinet, Inc.'s (NASDAQ:FTNT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?Fortinet's (NASDAQ:FTNT) stock is up by a considerable 9.5% over the past month. Given the company's impressive...


     

  • Insider Buying: Allyn knoche Just Spent CA$2.0m On FPX Nickel Corp. (CVE:FPX) Shares      Sat, 24 Oct 2020 10:50:41 -0400

    Insider Buying: Allyn knoche Just Spent CA$2.0m On FPX Nickel Corp. (CVE:FPX) SharesFPX Nickel Corp. (CVE:FPX) shareholders (or potential shareholders) will be happy to see that insider Allyn knoche...


    Insider Buying: Allyn knoche Just Spent CA$2.0m On FPX Nickel Corp. (CVE:FPX) SharesFPX Nickel Corp. (CVE:FPX) shareholders (or potential shareholders) will be happy to see that insider Allyn knoche...


     

  • Apollo Investor Revolt Swells Over Black’s Epstein Ties      Sat, 24 Oct 2020 10:49:51 -0400

    Apollo Investor Revolt Swells Over Black’s Epstein Ties(Bloomberg) -- It keeps getting worse for Leon Black.Over the past week, Black’s giant investment firm, Apollo Global Management Inc., has confronted one question after another about his decades-long relationship with convicted sex offender Jeffrey Epstein.First, his own board ordered an external review prompted by Black himself. Then a Pennsylvania pension fund paused new investments -- and the state of Connecticut has done the same. One major consultant -- a gatekeeper to $160 billion of investor commitments -- has urged clients to hold off, and another is considering taking similar action.Clients who for years enjoyed some of the best returns on Wall Street are reconsidering their ties to Apollo amid renewed scrutiny over Epstein, spurred by a New York Times report earlier this month and given fresh attention from an unsealed deposition of Epstein associate Ghislaine Maxwell.Investors distancing themselves from the firm show how serious the issue has become for Black and his general partners. Some clients aren’t convinced that the review, which will be handled by law firm Dechert LLP, will be enough to clear Black’s name, according to people familiar with the matter.A freeze in new money could hurt Apollo at a time when it’s trying to raise $20 billion for several new funds. The pandemic-spurred turmoil in the credit markets is a prime investing opportunity for the firm, which is known for buying struggling businesses. Apollo is seeking to take advantage of market dislocations as well as invest in private debt, people with knowledge of the matter said in April.Black’s growing troubles reflect the changing politics of the investing world, where major funds have become more sensitive to environmental, social and governance matters. The new focus means that even the prospect of lucrative returns may not be enough of a lure in the midst of a scandal.“While performance is always going to be an important factor, increasingly it’s not the only factor,” said Gerald O’Hara, an analyst at Jefferies Financial Group Inc. “In some respects, there’s some willingness to sacrifice performance for a company that’s run with good governance, good ethics.”Investment adviser Aksia told clients not to give new money to Apollo, Bloomberg reported Friday, while Connecticut said it is halting new investments with the firm. Earlier in the week, the Pennsylvania Public School Employees’ Retirement System said it would stop making additional investments in Apollo for now, and consultant Cambridge Associates is considering not recommending the firm to its pension and endowment clients.While Black faced pressure in the immediate aftermath of Epstein’s arrest last year, investor angst was rekindled by a New York Times report that he had wired at least $50 million to Epstein after his 2008 conviction for soliciting prostitution from a teenage girl. The article didn’t accuse Black of breaking the law. Apollo shares have fallen about 12% since the story was published on Oct. 12.“We are firmly committed to transparency,” Apollo said Friday in a statement, noting that Black has been communicating regularly with investors. “Although Apollo never did business with Jeffrey Epstein, Leon has requested an independent, outside review regarding his previous professional relationship with Mr. Epstein.”In a letter to Apollo’s limited partners this month, Black said he deeply regretted having had any involvement with Epstein. Black said he had turned to him for matters such as taxes, estate planning and philanthropy, and that nothing in the Times’ report was inconsistent with an earlier description of their ties.Read more: Leon Black’s Epstein Links Threaten Apollo’s FundraisingIt will be tough for investors to cut ties completely with Apollo as private equity funds typically lock up capital for years -- a trade-off many are willing to make with the promise of high-flying returns. And unless the inquiry unearths something more damning, clients may ultimately decide to look the other way, said three investors who asked not to be identified.It’s particularly unappealing for clients to pull away given the firm’s stellar returns. Apollo’s flagship private equity fund, which opened to investors in 2001, has delivered annual gains of 44%, Bloomberg reported in January.But even yield-starved investors looking to pump more money into private equity may choose to go elsewhere in future, as rivals flood the market with new offerings.“It’s a very competitive race for capital and one thing that we continue to see in fundraising is it is in many ways more similar to a political process than a capital-raising process,” said Sarah Sandstrom, partner at Campbell Lutyens, which helps private equity firms raise money. “You are telling your story, creating relationships with investors.”(Adds previous comment from Black in 12th paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.


    Apollo Investor Revolt Swells Over Black’s Epstein Ties(Bloomberg) -- It keeps getting worse for Leon Black.Over the past week, Black’s giant investment firm, Apollo Global Management Inc., has confronted one question after another about his decades-long relationship with convicted sex offender Jeffrey Epstein.First, his own board ordered an external review prompted by Black himself. Then a Pennsylvania pension fund paused new investments -- and the state of Connecticut has done the same. One major consultant -- a gatekeeper to $160 billion of investor commitments -- has urged clients to hold off, and another is considering taking similar action.Clients who for years enjoyed some of the best returns on Wall Street are reconsidering their ties to Apollo amid renewed scrutiny over Epstein, spurred by a New York Times report earlier this month and given fresh attention from an unsealed deposition of Epstein associate Ghislaine Maxwell.Investors distancing themselves from the firm show how serious the issue has become for Black and his general partners. Some clients aren’t convinced that the review, which will be handled by law firm Dechert LLP, will be enough to clear Black’s name, according to people familiar with the matter.A freeze in new money could hurt Apollo at a time when it’s trying to raise $20 billion for several new funds. The pandemic-spurred turmoil in the credit markets is a prime investing opportunity for the firm, which is known for buying struggling businesses. Apollo is seeking to take advantage of market dislocations as well as invest in private debt, people with knowledge of the matter said in April.Black’s growing troubles reflect the changing politics of the investing world, where major funds have become more sensitive to environmental, social and governance matters. The new focus means that even the prospect of lucrative returns may not be enough of a lure in the midst of a scandal.“While performance is always going to be an important factor, increasingly it’s not the only factor,” said Gerald O’Hara, an analyst at Jefferies Financial Group Inc. “In some respects, there’s some willingness to sacrifice performance for a company that’s run with good governance, good ethics.”Investment adviser Aksia told clients not to give new money to Apollo, Bloomberg reported Friday, while Connecticut said it is halting new investments with the firm. Earlier in the week, the Pennsylvania Public School Employees’ Retirement System said it would stop making additional investments in Apollo for now, and consultant Cambridge Associates is considering not recommending the firm to its pension and endowment clients.While Black faced pressure in the immediate aftermath of Epstein’s arrest last year, investor angst was rekindled by a New York Times report that he had wired at least $50 million to Epstein after his 2008 conviction for soliciting prostitution from a teenage girl. The article didn’t accuse Black of breaking the law. Apollo shares have fallen about 12% since the story was published on Oct. 12.“We are firmly committed to transparency,” Apollo said Friday in a statement, noting that Black has been communicating regularly with investors. “Although Apollo never did business with Jeffrey Epstein, Leon has requested an independent, outside review regarding his previous professional relationship with Mr. Epstein.”In a letter to Apollo’s limited partners this month, Black said he deeply regretted having had any involvement with Epstein. Black said he had turned to him for matters such as taxes, estate planning and philanthropy, and that nothing in the Times’ report was inconsistent with an earlier description of their ties.Read more: Leon Black’s Epstein Links Threaten Apollo’s FundraisingIt will be tough for investors to cut ties completely with Apollo as private equity funds typically lock up capital for years -- a trade-off many are willing to make with the promise of high-flying returns. And unless the inquiry unearths something more damning, clients may ultimately decide to look the other way, said three investors who asked not to be identified.It’s particularly unappealing for clients to pull away given the firm’s stellar returns. Apollo’s flagship private equity fund, which opened to investors in 2001, has delivered annual gains of 44%, Bloomberg reported in January.But even yield-starved investors looking to pump more money into private equity may choose to go elsewhere in future, as rivals flood the market with new offerings.“It’s a very competitive race for capital and one thing that we continue to see in fundraising is it is in many ways more similar to a political process than a capital-raising process,” said Sarah Sandstrom, partner at Campbell Lutyens, which helps private equity firms raise money. “You are telling your story, creating relationships with investors.”(Adds previous comment from Black in 12th paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.


     

  • Sandra Pessin of Nephros, Inc. (NASDAQ:NEPH) Just Spent US$300k On Shares      Sat, 24 Oct 2020 10:47:41 -0400

    Sandra Pessin of Nephros, Inc. (NASDAQ:NEPH) Just Spent US$300k On SharesInvestors who take an interest in Nephros, Inc. (NASDAQ:NEPH) should definitely note that insider Sandra Pessin...


    Sandra Pessin of Nephros, Inc. (NASDAQ:NEPH) Just Spent US$300k On SharesInvestors who take an interest in Nephros, Inc. (NASDAQ:NEPH) should definitely note that insider Sandra Pessin...


     

  • Here's What We Think About First Foundation's (NASDAQ:FFWM) CEO Pay      Sat, 24 Oct 2020 10:46:44 -0400

    Here's What We Think About First Foundation's (NASDAQ:FFWM) CEO PayScott Farris Kavanaugh became the CEO of First Foundation Inc. (NASDAQ:FFWM) in 2009, and we think it's a good time to...


    Here's What We Think About First Foundation's (NASDAQ:FFWM) CEO PayScott Farris Kavanaugh became the CEO of First Foundation Inc. (NASDAQ:FFWM) in 2009, and we think it's a good time to...


     

  • Californians Face Year’s Biggest Power Shutoffs on Fire Risk      Sat, 24 Oct 2020 10:44:40 -0400

    Californians Face Year’s Biggest Power Shutoffs on Fire Risk(Bloomberg) -- Californians are facing the largest mass blackout so far this year as the state’s biggest utility, PG&E Corp., prepares power shutoffs to prevent live wires from falling into dry brush and igniting wildfires with ferocious winds sweeping across the region.The company may preemptively cut power to 466,000 homes and businesses -- an estimated 1.4 million people -- across Northern California starting early Sunday, according to its website. The outages are poised to hit large swaths of the San Francisco Bay area, the Sierra Nevada foothills, the Central Valley and the Central Coast.The potential blackouts would be the latest blow for a state that’s been battered by extreme weather and has already seen a record 4.1 million acres (1.66 million hectares) scorched this year. PG&E has preemptively cut power four times in 2020 to prevent falling wires from igniting blazes in a region that’s tinder dry from heat and drought. The new round of outages would be the biggest by far, stretching across 38 counties.Winds starting this weekend are forecast to reach 70 miles (113 kilometers) per hour in the northern part of the state, with gusts expected to last through Tuesday morning. By Monday, humidity will be as low as 6% in Redding and just 5% in Grass Valley, according to the National Weather Service. It comes as the state is already riddled with dry brush and grasses due to the hottest average temperatures over the last six months, according to records that go back 126 years, said Scott Strenfel, PG&E’s head of meteorology and fire science.The blackouts may hit densely populated parts of the San Francisco metropolitan area, including portions of Oakland, Berkeley and Marin County -- cutting power to many residents as they are working from home due to the coronavirus pandemic. San Francisco, at relatively low risk of fires, is the only county in the Bay Area region not expected to be affected.PG&E isn’t the only utility warning of outages. Pacific Power, owned by Warren Buffett’s Berkshire Hathaway Inc., said Friday that it could switch off power for about 5,800 customers in Northern California and Southern Oregon on Sunday due to the gusts, according to a statement.Much of the U.S. West is at risk from wildfires as dry weather and stiff winds turn hillsides, forests and scrub land into tinderboxes. In Colorado, two of the largest fires in state history have forced the closure of Rocky Mountain National Park and triggered the evacuation of nearby towns. And in Utah, Berkshire’s Rocky Mountain Power warned earlier this week it may cut power to about 1,800 customers in Sundance and Summit Park due to fire risk.More than 3.1 million people across California will be in high-risk zones, including the cities of Sacramento, Stockton, and Fairfield, the U.S. Storm Prediction Center said in its long-range forecast.The looming outages come on the heels of a blistering heat wave that gripped California earlier this month, driving temperatures to record daily highs. In August, a freak lightning storm sparked more than 150 wildfires in 24 hours. Days before that, the state’s grid operator ordered the first rotating outages since the Enron-era energy crisis of 2001 as scorching weather sent electricity demand surging.PG&E began resorting to preventative shutoffs after its equipment caused some of California’s worst blazes, forcing the company into bankruptcy last year. PG&E emerged from Chapter 11 in July after having paid $25.5 billion to resolve fire claims.“They have a lot of work to do not just to restore their power but to restore the trust that they have failed to earn over the course of decades,” Governor Gavin Newsom said during a briefing Friday. “That is self-evident to anyone living in the Bay Area.”(Updates forecast in fourth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.


    Californians Face Year’s Biggest Power Shutoffs on Fire Risk(Bloomberg) -- Californians are facing the largest mass blackout so far this year as the state’s biggest utility, PG&E Corp., prepares power shutoffs to prevent live wires from falling into dry brush and igniting wildfires with ferocious winds sweeping across the region.The company may preemptively cut power to 466,000 homes and businesses -- an estimated 1.4 million people -- across Northern California starting early Sunday, according to its website. The outages are poised to hit large swaths of the San Francisco Bay area, the Sierra Nevada foothills, the Central Valley and the Central Coast.The potential blackouts would be the latest blow for a state that’s been battered by extreme weather and has already seen a record 4.1 million acres (1.66 million hectares) scorched this year. PG&E has preemptively cut power four times in 2020 to prevent falling wires from igniting blazes in a region that’s tinder dry from heat and drought. The new round of outages would be the biggest by far, stretching across 38 counties.Winds starting this weekend are forecast to reach 70 miles (113 kilometers) per hour in the northern part of the state, with gusts expected to last through Tuesday morning. By Monday, humidity will be as low as 6% in Redding and just 5% in Grass Valley, according to the National Weather Service. It comes as the state is already riddled with dry brush and grasses due to the hottest average temperatures over the last six months, according to records that go back 126 years, said Scott Strenfel, PG&E’s head of meteorology and fire science.The blackouts may hit densely populated parts of the San Francisco metropolitan area, including portions of Oakland, Berkeley and Marin County -- cutting power to many residents as they are working from home due to the coronavirus pandemic. San Francisco, at relatively low risk of fires, is the only county in the Bay Area region not expected to be affected.PG&E isn’t the only utility warning of outages. Pacific Power, owned by Warren Buffett’s Berkshire Hathaway Inc., said Friday that it could switch off power for about 5,800 customers in Northern California and Southern Oregon on Sunday due to the gusts, according to a statement.Much of the U.S. West is at risk from wildfires as dry weather and stiff winds turn hillsides, forests and scrub land into tinderboxes. In Colorado, two of the largest fires in state history have forced the closure of Rocky Mountain National Park and triggered the evacuation of nearby towns. And in Utah, Berkshire’s Rocky Mountain Power warned earlier this week it may cut power to about 1,800 customers in Sundance and Summit Park due to fire risk.More than 3.1 million people across California will be in high-risk zones, including the cities of Sacramento, Stockton, and Fairfield, the U.S. Storm Prediction Center said in its long-range forecast.The looming outages come on the heels of a blistering heat wave that gripped California earlier this month, driving temperatures to record daily highs. In August, a freak lightning storm sparked more than 150 wildfires in 24 hours. Days before that, the state’s grid operator ordered the first rotating outages since the Enron-era energy crisis of 2001 as scorching weather sent electricity demand surging.PG&E began resorting to preventative shutoffs after its equipment caused some of California’s worst blazes, forcing the company into bankruptcy last year. PG&E emerged from Chapter 11 in July after having paid $25.5 billion to resolve fire claims.“They have a lot of work to do not just to restore their power but to restore the trust that they have failed to earn over the course of decades,” Governor Gavin Newsom said during a briefing Friday. “That is self-evident to anyone living in the Bay Area.”(Updates forecast in fourth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.


     

  • Results: Meritage Homes Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates      Sat, 24 Oct 2020 10:44:35 -0400

    Results: Meritage Homes Corporation Exceeded Expectations And The Consensus Has Updated Its EstimatesMeritage Homes Corporation (NYSE:MTH) just released its quarterly report and things are looking bullish. It was...


    Results: Meritage Homes Corporation Exceeded Expectations And The Consensus Has Updated Its EstimatesMeritage Homes Corporation (NYSE:MTH) just released its quarterly report and things are looking bullish. It was...


     

  • Should You Be Impressed By Entergy's (NYSE:ETR) Returns on Capital?      Sat, 24 Oct 2020 10:41:24 -0400

    Should You Be Impressed By Entergy's (NYSE:ETR) Returns on Capital?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...


    Should You Be Impressed By Entergy's (NYSE:ETR) Returns on Capital?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...


     

  • M&T Bank Corporation Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next      Sat, 24 Oct 2020 10:41:24 -0400

    M&T Bank Corporation Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen NextIt's been a good week for M&T Bank Corporation (NYSE:MTB) shareholders, because the company has just released its...


    M&T Bank Corporation Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen NextIt's been a good week for M&T Bank Corporation (NYSE:MTB) shareholders, because the company has just released its...


     

  • Leading Rehabilitation Providers Partner in Key Telehealth Research Study in Response to COVID-19 Pandemic      Sat, 24 Oct 2020 10:41:00 -0400

    Leading Rehabilitation Providers Partner in Key Telehealth Research Study in Response to COVID-19 PandemicBrooks Rehabilitation is pleased to announce the launch of an essential research study that will advance the use of telehealth for rehabilitation in response to public health crises such as the COVID-19 pandemic. Partners Madonna Rehabilitation Hospital and Mary Free Bed Rehabilitation Hospital complete the team of leading rehabilitation providers supporting the creation and deployment of the study, with the goal to obtain vital data and feedback that will be used to shape the future of telehealth for patients and providers.


    Leading Rehabilitation Providers Partner in Key Telehealth Research Study in Response to COVID-19 PandemicBrooks Rehabilitation is pleased to announce the launch of an essential research study that will advance the use of telehealth for rehabilitation in response to public health crises such as the COVID-19 pandemic. Partners Madonna Rehabilitation Hospital and Mary Free Bed Rehabilitation Hospital complete the team of leading rehabilitation providers supporting the creation and deployment of the study, with the goal to obtain vital data and feedback that will be used to shape the future of telehealth for patients and providers.


     

  • Don't Race Out To Buy Mesabi Trust (NYSE:MSB) Just Because It's Going Ex-Dividend      Sat, 24 Oct 2020 10:38:26 -0400

    Don't Race Out To Buy Mesabi Trust (NYSE:MSB) Just Because It's Going Ex-DividendSome investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...


    Don't Race Out To Buy Mesabi Trust (NYSE:MSB) Just Because It's Going Ex-DividendSome investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...


     

  • What Type Of Shareholders Make Up Calyxt, Inc.'s (NASDAQ:CLXT) Share Registry?      Sat, 24 Oct 2020 10:35:50 -0400

    What Type Of Shareholders Make Up Calyxt, Inc.'s (NASDAQ:CLXT) Share Registry?A look at the shareholders of Calyxt, Inc. (NASDAQ:CLXT) can tell us which group is most powerful. Institutions often...


    What Type Of Shareholders Make Up Calyxt, Inc.'s (NASDAQ:CLXT) Share Registry?A look at the shareholders of Calyxt, Inc. (NASDAQ:CLXT) can tell us which group is most powerful. Institutions often...


     

  • There's A Lot To Like About Morgan Stanley's (NYSE:MS) Upcoming US$0.35 Dividend      Sat, 24 Oct 2020 10:35:16 -0400

    There's A Lot To Like About Morgan Stanley's (NYSE:MS) Upcoming US$0.35 DividendSome investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...


    There's A Lot To Like About Morgan Stanley's (NYSE:MS) Upcoming US$0.35 DividendSome investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...


     

  • Results: Metropolitan Bank Holding Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates      Sat, 24 Oct 2020 10:31:58 -0400

    Results: Metropolitan Bank Holding Corp. Exceeded Expectations And The Consensus Has Updated Its EstimatesMetropolitan Bank Holding Corp. (NYSE:MCB) last week reported its latest quarterly results, which makes it a good time...


    Results: Metropolitan Bank Holding Corp. Exceeded Expectations And The Consensus Has Updated Its EstimatesMetropolitan Bank Holding Corp. (NYSE:MCB) last week reported its latest quarterly results, which makes it a good time...


     

  • Estimating The Intrinsic Value Of Brookfield Renewable Corporation (TSE:BEPC)      Sat, 24 Oct 2020 10:30:22 -0400

    Estimating The Intrinsic Value Of Brookfield Renewable Corporation (TSE:BEPC)Does the October share price for Brookfield Renewable Corporation (TSE:BEPC) reflect what it's really worth? Today, we...


    Estimating The Intrinsic Value Of Brookfield Renewable Corporation (TSE:BEPC)Does the October share price for Brookfield Renewable Corporation (TSE:BEPC) reflect what it's really worth? Today, we...


     

  • Celebrate REALTOR Safety Year-Round with a Customized Safety Culture Program      Sat, 24 Oct 2020 10:30:00 -0400

    Celebrate REALTOR Safety Year-Round with a Customized Safety Culture ProgramThe Beverly Carter Foundation (BCF) is proud to introduce a three-part training series to assist leadership throughout the real estate industry in implementing sustainable safety strategies for their companies, associations, and employees year-round in order to prevent lone-worker tragedies and long-term harm. The new normal of COVID-19 restrictions, limited showings, increase of virtual communication, and one-on-one meetings are presenting new challenges. In order to support this safety initiative, BCF's first training, Leadership: Creating a Safety Culture Year-Round, will be held as a webinar Tuesday, October 27, 2020.


    Celebrate REALTOR Safety Year-Round with a Customized Safety Culture ProgramThe Beverly Carter Foundation (BCF) is proud to introduce a three-part training series to assist leadership throughout the real estate industry in implementing sustainable safety strategies for their companies, associations, and employees year-round in order to prevent lone-worker tragedies and long-term harm. The new normal of COVID-19 restrictions, limited showings, increase of virtual communication, and one-on-one meetings are presenting new challenges. In order to support this safety initiative, BCF's first training, Leadership: Creating a Safety Culture Year-Round, will be held as a webinar Tuesday, October 27, 2020.


     

  • Results: Mattel, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates      Sat, 24 Oct 2020 10:29:02 -0400

    Results: Mattel, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMattel, Inc. (NASDAQ:MAT) just released its third-quarter report and things are looking bullish. It was a solid...


    Results: Mattel, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMattel, Inc. (NASDAQ:MAT) just released its third-quarter report and things are looking bullish. It was a solid...


     

  • Results: Business First Bancshares, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates      Sat, 24 Oct 2020 10:25:36 -0400

    Results: Business First Bancshares, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesBusiness First Bancshares, Inc. (NASDAQ:BFST) defied analyst predictions to release its quarterly results, which were...


    Results: Business First Bancshares, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesBusiness First Bancshares, Inc. (NASDAQ:BFST) defied analyst predictions to release its quarterly results, which were...


     

  • Here's What Bitauto Holdings Limited's (NYSE:BITA) Shareholder Ownership Structure Looks Like      Sat, 24 Oct 2020 10:24:44 -0400

    Here's What Bitauto Holdings Limited's (NYSE:BITA) Shareholder Ownership Structure Looks LikeThe big shareholder groups in Bitauto Holdings Limited (NYSE:BITA) have power over the company. Institutions will...


    Here's What Bitauto Holdings Limited's (NYSE:BITA) Shareholder Ownership Structure Looks LikeThe big shareholder groups in Bitauto Holdings Limited (NYSE:BITA) have power over the company. Institutions will...


     

  • Southwest Airlines Co. (NYSE:LUV) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?      Sat, 24 Oct 2020 10:22:35 -0400

    Southwest Airlines Co. (NYSE:LUV) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?Southwest Airlines Co. (NYSE:LUV) just released its quarterly report and things are looking bullish. Revenues and...


    Southwest Airlines Co. (NYSE:LUV) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?Southwest Airlines Co. (NYSE:LUV) just released its quarterly report and things are looking bullish. Revenues and...


     

  • If You Had Bought Antibe Therapeutics (CVE:ATE) Shares Three Years Ago You'd Have Earned 289% Returns      Sat, 24 Oct 2020 10:19:15 -0400

    If You Had Bought Antibe Therapeutics (CVE:ATE) Shares Three Years Ago You'd Have Earned 289% ReturnsIt hasn't been the best quarter for Antibe Therapeutics Inc. (CVE:ATE) shareholders, since the share price has fallen...


    If You Had Bought Antibe Therapeutics (CVE:ATE) Shares Three Years Ago You'd Have Earned 289% ReturnsIt hasn't been the best quarter for Antibe Therapeutics Inc. (CVE:ATE) shareholders, since the share price has fallen...


     

  • Four Days Left To Buy Bridgemarq Real Estate Services Inc. (TSE:BRE) Before The Ex-Dividend Date      Sat, 24 Oct 2020 10:16:24 -0400

    Four Days Left To Buy Bridgemarq Real Estate Services Inc. (TSE:BRE) Before The Ex-Dividend DateRegular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Bridgemarq...


    Four Days Left To Buy Bridgemarq Real Estate Services Inc. (TSE:BRE) Before The Ex-Dividend DateRegular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Bridgemarq...


     

  • Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium      Sat, 24 Oct 2020 10:15:00 -0400

    Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium* Preliminary Clinical Activity and Safety Profile Support Advancing to Dose Expansion in Multiple Tumor Types  * Recommended Phase 2 Dose Determination Ongoing * Preclinical Combination Data for Lead Drug Candidate Repotrectinib in both KRAS Tumor Models and Pediatric Neuroblastoma Tumor Models Also Presented * Conference Call Scheduled for 11:00 a.m. Eastern Time SAN DIEGO, Oct. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase 1 dose finding portion of its SHIELD-1 study of drug candidate, TPX-0022, a potent inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R. The initial data highlighted preliminary clinical activity, including objective responses across multiple tumor types and a generally tolerable safety profile.The findings were reported in a late-breaking oral presentation by David Hong, M.D., Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center in the plenary session of the Molecular Targets and Cancer Therapeutics virtual symposium hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR).“Oncogenic alterations in MET – including exon 14 deletion, amplifications, fusions and activating kinase domain mutations – occur in many tumor types and patients continue to have limited available therapies,” said Dr. Hong. “The initial data reported today for TPX-0022 is encouraging because it represents the potential for a new targeted therapy to improve the outcome in a wide range of MET-driven cancers.”TPX-0022, Phase 1 Initial Clinical Data Twenty-two patients were treated across four dose levels from Sept. 2019 to the data cut-off date of Oct. 15, 2020. Patients included those with MET-altered non-small cell lung cancer (n=13), colorectal cancer (n=4), gastric or gastroesophageal (GE) junction cancer (n=4) and glioblastoma (n=1).The median number of prior therapies was three (range 1 to 6), with all patients having received at least one prior line of chemotherapy and/or immunotherapy and the majority of patients having received multiple rounds of prior combination chemotherapy. Sixty-eight percent of patients had a baseline ECOG performance score of 1.Preliminary efficacy data was available for 15 evaluable patients with baseline measurable disease and at least one post-baseline scan.As of the 15 October 2020 data cut-off date:Preliminary Safety and Pharmacokinetic (PK) Results (n=22) * A total of 22 patients with MET-dysregulated advanced solid tumors were treated with TPX-0022 at dose levels from 20 mg once daily (QD) to 120 mg QD. * TPX-0022 was generally well tolerated, with the most frequent treatment emergent adverse event (TEAE) being Grade 1 or 2 dizziness. * TEAEs reported in greater than 20 percent of patients were dizziness (55%); lipase increased (32%); fatigue (32%); amylase increased (27%); nausea (27%); vomiting (27%); constipation (23%); and anemia (23%). * The majority of treatment related adverse events (TRAEs) were Grade 1 or 2 and there were no Grade 4 or 5 TRAEs * The maximum tolerated dose had not been determined, with one dose-limiting toxicity of treatment-related Grade 2 dizziness at 120 mg QD.  * PK data suggested sustained MET inhibition throughout the dosing interval across all doses.Preliminary Efficacy Results (n=15) * A total of 15 patients were evaluable for efficacy by investigator assessment, including 10 who were MET TKI-naïve: four with colorectal cancer (CRC), three with non-small cell lung cancer (NSCLC), and three with gastric or GE junction cancer (GC or GEJ). In addition, five patients were MET TKI-pretreated, all with NSCLC. * Of 10 MET TKI-naïve patients, five achieved a partial response, including three with GC or GEJ cancer, one with CRC, and one with NSCLC. All three evaluable patients with gastric or GEJ tumors achieved a response. * Of the five responses, three patients achieved a confirmed response, and two patients remained on treatment in a response awaiting confirmation at the time of the data cut-off. * Of the five MET TKI-pretreated NSCLC patients, three patients treated with multiple rounds of prior therapy achieved a best response of stable disease with two patients showing tumor measurement improvements (-27%, and -75% accordingly). * Nine of 15 patients (9/15) achieved clinical benefit (confirmed and unconfirmed partial response or stable disease). * Six of 15 patients (6/15) remained on treatment with duration of treatment ranging from 7.6+ to 34+ weeks.“We are encouraged by the emerging early safety and efficacy data across multiple tumor types, including the high unmet medical need area within MET-amplified gastric cancer where there are no approved targeted therapies,” said Mohammad Hirmand, M.D., chief medical officer. “MET driven cancers affect a large and growing population of patients who have limited therapeutic options. Based on these early study findings, we look forward to advancing the development of TPX-0022.”The company anticipates initiating Phase 1 dose expansion after determining the recommended Phase 2 dose. Turning Point plans to discuss the ongoing Phase 1 SHIELD-1 study with the Food and Drug Administration (FDA) to potentially modify the trial into a registrational Phase 1/2 design. The company is targeting initiation of the Phase 2 portion in the second half of 2021, pending FDA feedback. In parallel, based on the SHIELD-1 study initial findings, a combination study with TPX-0022 and an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with EGFR mutated MET-amplified NSCLC is also planned for initiation in the second half of 2021.Repotrectinib Poster Presentations In addition, preclinical data for the company’s lead drug candidate repotrectinib were reported in two poster presentations.The first poster expanded on previous work presented in June at AACR 2020 with additional preclinical data of repotrectinib in combination with the KRAS-G12C inhibitor, AMG-510, in a NSCLC xenograft tumor model. In preclinical studies, repotrectinib significantly enhanced efficacy of AMG-510 and showed a marked survival benefit in a KRAS G12C xenograft model when compared to AMG-510 alone.Repotrectinib previously showed synergy in preclinical models with AMG-510 and inhibited KRAS G12C tumor cell proliferation, suppressed receptor tyrosine kinase upregulation induced by AMG-510, and reduced KRAS G12C tumor cell cytokine release. Similar results have since been obtained with other KRAS G12C inhibitors.With the new results presented in a KRAS G12C xenograft tumor model, and previous data shown with repotrectinib in combination with a MEK inhibitor (presented at AACR 2020), the company now plans to initiate a clinical combination study in KRAS mutant NSCLC in mid-2021. Further details on the design will be shared at the time of study initiation.The second poster showed preclinical studies of repotrectinib as monotherapy and in combination with irinotecan and temozolomide in neuroblastoma cell lines and pediatric patient-derived xenograft (PDX) models. Repotrectinib combined with chemotherapy demonstrated increased anti-tumor activity compared to chemotherapy alone in an ALK-mutant neuroblastoma PDX model.“With a growing body of supportive preclinical data, we are encouraged by the potentially broader role for repotrectinib across the treatment landscape,” said Dr. Hirmand. “Repotrectinib’s inhibition of the cancer signaling pathways of SRC, FAK and JAK2, and its generally well-tolerated safety profile make it an ideal candidate for combination therapy. We look forward to advancing our combination strategy toward the initiation of clinical studies in 2021.”Webcast and Conference Call Turning Point will host a webcast and conference call accompanied by a slide presentation to discuss the results from the SHIELD-1 Phase 1 study of TPX-0022 at 11:00 a.m. ET/8:00 a.m. PT today. Athena Countouriotis, M.D., president and chief executive officer, will host the call, which will also include Dr. Hirmand and Dr. Hong.The discussion will be accessible through the "Investors" section of tptherapeutics.com or by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID 8655648. A replay will be available through the "Investors" section of www.tptherapeutics.com.About Turning Point Therapeutics Inc. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study called TRIDENT-1 in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is in a Phase 1 study called SHIELD-1 in patients with advanced or metastatic solid tumors harboring genetic alterations in MET; RET-inhibitor TPX-0046, which is in a Phase 1/2 study of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and ALK-inhibitor TPX-0131, which is in IND-enabling studies. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of TPX-0022 and repotrectinib, the results, conduct, progress and timing of the Phase 1 SHIELD-1 clinical study of TPX-0022, and preclinical studies of repotrectinib, plans regarding future clinical studies and regulatory discussions and the regulatory approval path for TPX-0022. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.Contact: Jim Mazzola jim.mazzola@tptherapeutics.com 858-342-8272


    Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium* Preliminary Clinical Activity and Safety Profile Support Advancing to Dose Expansion in Multiple Tumor Types  * Recommended Phase 2 Dose Determination Ongoing * Preclinical Combination Data for Lead Drug Candidate Repotrectinib in both KRAS Tumor Models and Pediatric Neuroblastoma Tumor Models Also Presented * Conference Call Scheduled for 11:00 a.m. Eastern Time SAN DIEGO, Oct. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase 1 dose finding portion of its SHIELD-1 study of drug candidate, TPX-0022, a potent inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R. The initial data highlighted preliminary clinical activity, including objective responses across multiple tumor types and a generally tolerable safety profile.The findings were reported in a late-breaking oral presentation by David Hong, M.D., Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center in the plenary session of the Molecular Targets and Cancer Therapeutics virtual symposium hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR).“Oncogenic alterations in MET – including exon 14 deletion, amplifications, fusions and activating kinase domain mutations – occur in many tumor types and patients continue to have limited available therapies,” said Dr. Hong. “The initial data reported today for TPX-0022 is encouraging because it represents the potential for a new targeted therapy to improve the outcome in a wide range of MET-driven cancers.”TPX-0022, Phase 1 Initial Clinical Data Twenty-two patients were treated across four dose levels from Sept. 2019 to the data cut-off date of Oct. 15, 2020. Patients included those with MET-altered non-small cell lung cancer (n=13), colorectal cancer (n=4), gastric or gastroesophageal (GE) junction cancer (n=4) and glioblastoma (n=1).The median number of prior therapies was three (range 1 to 6), with all patients having received at least one prior line of chemotherapy and/or immunotherapy and the majority of patients having received multiple rounds of prior combination chemotherapy. Sixty-eight percent of patients had a baseline ECOG performance score of 1.Preliminary efficacy data was available for 15 evaluable patients with baseline measurable disease and at least one post-baseline scan.As of the 15 October 2020 data cut-off date:Preliminary Safety and Pharmacokinetic (PK) Results (n=22) * A total of 22 patients with MET-dysregulated advanced solid tumors were treated with TPX-0022 at dose levels from 20 mg once daily (QD) to 120 mg QD. * TPX-0022 was generally well tolerated, with the most frequent treatment emergent adverse event (TEAE) being Grade 1 or 2 dizziness. * TEAEs reported in greater than 20 percent of patients were dizziness (55%); lipase increased (32%); fatigue (32%); amylase increased (27%); nausea (27%); vomiting (27%); constipation (23%); and anemia (23%). * The majority of treatment related adverse events (TRAEs) were Grade 1 or 2 and there were no Grade 4 or 5 TRAEs * The maximum tolerated dose had not been determined, with one dose-limiting toxicity of treatment-related Grade 2 dizziness at 120 mg QD.  * PK data suggested sustained MET inhibition throughout the dosing interval across all doses.Preliminary Efficacy Results (n=15) * A total of 15 patients were evaluable for efficacy by investigator assessment, including 10 who were MET TKI-naïve: four with colorectal cancer (CRC), three with non-small cell lung cancer (NSCLC), and three with gastric or GE junction cancer (GC or GEJ). In addition, five patients were MET TKI-pretreated, all with NSCLC. * Of 10 MET TKI-naïve patients, five achieved a partial response, including three with GC or GEJ cancer, one with CRC, and one with NSCLC. All three evaluable patients with gastric or GEJ tumors achieved a response. * Of the five responses, three patients achieved a confirmed response, and two patients remained on treatment in a response awaiting confirmation at the time of the data cut-off. * Of the five MET TKI-pretreated NSCLC patients, three patients treated with multiple rounds of prior therapy achieved a best response of stable disease with two patients showing tumor measurement improvements (-27%, and -75% accordingly). * Nine of 15 patients (9/15) achieved clinical benefit (confirmed and unconfirmed partial response or stable disease). * Six of 15 patients (6/15) remained on treatment with duration of treatment ranging from 7.6+ to 34+ weeks.“We are encouraged by the emerging early safety and efficacy data across multiple tumor types, including the high unmet medical need area within MET-amplified gastric cancer where there are no approved targeted therapies,” said Mohammad Hirmand, M.D., chief medical officer. “MET driven cancers affect a large and growing population of patients who have limited therapeutic options. Based on these early study findings, we look forward to advancing the development of TPX-0022.”The company anticipates initiating Phase 1 dose expansion after determining the recommended Phase 2 dose. Turning Point plans to discuss the ongoing Phase 1 SHIELD-1 study with the Food and Drug Administration (FDA) to potentially modify the trial into a registrational Phase 1/2 design. The company is targeting initiation of the Phase 2 portion in the second half of 2021, pending FDA feedback. In parallel, based on the SHIELD-1 study initial findings, a combination study with TPX-0022 and an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with EGFR mutated MET-amplified NSCLC is also planned for initiation in the second half of 2021.Repotrectinib Poster Presentations In addition, preclinical data for the company’s lead drug candidate repotrectinib were reported in two poster presentations.The first poster expanded on previous work presented in June at AACR 2020 with additional preclinical data of repotrectinib in combination with the KRAS-G12C inhibitor, AMG-510, in a NSCLC xenograft tumor model. In preclinical studies, repotrectinib significantly enhanced efficacy of AMG-510 and showed a marked survival benefit in a KRAS G12C xenograft model when compared to AMG-510 alone.Repotrectinib previously showed synergy in preclinical models with AMG-510 and inhibited KRAS G12C tumor cell proliferation, suppressed receptor tyrosine kinase upregulation induced by AMG-510, and reduced KRAS G12C tumor cell cytokine release. Similar results have since been obtained with other KRAS G12C inhibitors.With the new results presented in a KRAS G12C xenograft tumor model, and previous data shown with repotrectinib in combination with a MEK inhibitor (presented at AACR 2020), the company now plans to initiate a clinical combination study in KRAS mutant NSCLC in mid-2021. Further details on the design will be shared at the time of study initiation.The second poster showed preclinical studies of repotrectinib as monotherapy and in combination with irinotecan and temozolomide in neuroblastoma cell lines and pediatric patient-derived xenograft (PDX) models. Repotrectinib combined with chemotherapy demonstrated increased anti-tumor activity compared to chemotherapy alone in an ALK-mutant neuroblastoma PDX model.“With a growing body of supportive preclinical data, we are encouraged by the potentially broader role for repotrectinib across the treatment landscape,” said Dr. Hirmand. “Repotrectinib’s inhibition of the cancer signaling pathways of SRC, FAK and JAK2, and its generally well-tolerated safety profile make it an ideal candidate for combination therapy. We look forward to advancing our combination strategy toward the initiation of clinical studies in 2021.”Webcast and Conference Call Turning Point will host a webcast and conference call accompanied by a slide presentation to discuss the results from the SHIELD-1 Phase 1 study of TPX-0022 at 11:00 a.m. ET/8:00 a.m. PT today. Athena Countouriotis, M.D., president and chief executive officer, will host the call, which will also include Dr. Hirmand and Dr. Hong.The discussion will be accessible through the "Investors" section of tptherapeutics.com or by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID 8655648. A replay will be available through the "Investors" section of www.tptherapeutics.com.About Turning Point Therapeutics Inc. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study called TRIDENT-1 in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is in a Phase 1 study called SHIELD-1 in patients with advanced or metastatic solid tumors harboring genetic alterations in MET; RET-inhibitor TPX-0046, which is in a Phase 1/2 study of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and ALK-inhibitor TPX-0131, which is in IND-enabling studies. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of TPX-0022 and repotrectinib, the results, conduct, progress and timing of the Phase 1 SHIELD-1 clinical study of TPX-0022, and preclinical studies of repotrectinib, plans regarding future clinical studies and regulatory discussions and the regulatory approval path for TPX-0022. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.Contact: Jim Mazzola jim.mazzola@tptherapeutics.com 858-342-8272


     

  • We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely      Sat, 24 Oct 2020 10:13:56 -0400

    We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...


    We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...


     

  • Lakeland Bancorp, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions      Sat, 24 Oct 2020 10:13:12 -0400

    Lakeland Bancorp, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsShareholders of Lakeland Bancorp, Inc. (NASDAQ:LBAI) will be pleased this week, given that the stock price is up 11...


    Lakeland Bancorp, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsShareholders of Lakeland Bancorp, Inc. (NASDAQ:LBAI) will be pleased this week, given that the stock price is up 11...


     



Copyright 1997-2011 SQLData System, Inc  All rights reserved.

Comments, or suggestions? Send to info2 at sqldata.com

This site is powered by SQLData SOAP Server